Spots Global Cancer Trial Database for venetoclax
Every month we try and update this database with for venetoclax cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | NCT03513562 | Chronic Lymphoc... Ibrutinib Resis... | Ibrutinib Laboratory Biom... Venetoclax | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia | NCT02689440 | Chronic Phase C... Philadelphia Ch... | Dasatinib Laboratory Biom... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | NCT05365035 | Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Venetoclax Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | NCT05799079 | Recurrent Acute... | Venetoclax Decitabine Cedazuridine Bone Marrow Asp... Biospecimen Col... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | NCT03504644 | B Acute Lymphob... Lymphoblasts 5 ... Recurrent Adult... Recurrent Child... Refractory Acut... T Acute Lymphob... | Laboratory Biom... Venetoclax Vincristine Lip... | 18 Years - | Eastern Cooperative Oncology Group | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | NCT06210750 | T Acute Lymphob... T Lymphoblastic... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | NCT04128501 | Acute Bilineal ... Acute Biphenoty... Acute Myeloid L... Mixed Phenotype... T Acute Lymphob... Therapy-Related... | Azacitidine Venetoclax | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | NCT03217838 | Acute Myeloid L... | AZD2811 Azacitidine Venetoclax | 18 Years - 130 Years | AstraZeneca | |
| A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | NCT05268003 | Acute Lymphobla... Leukemia | Ponatinib Venetoclax Mini-hyper CVD | 12 Years - | M.D. Anderson Cancer Center | |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | NCT04608318 | Chronic Lymphoi... | Ibrutinib Venetoclax Obinutuzumab | 18 Years - | German CLL Study Group | |
| Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia | NCT04964505 | Acute Myeloid L... | Azacitidine Uproleselan Venetoclax | 18 Years - | University of California, Davis | |
| Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | NCT04172844 | Acute Myelogeno... | Azacitidine Venetoclax Pevonedistat | 18 Years - | Medical College of Wisconsin | |
| Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 | NCT04070768 | Acute Myeloid L... | Gemtuzumab Ozog... Venetoclax | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT06428019 | Chronic Lymphoc... | Venetoclax Acalabrutinib Obinutuzumab | 18 Years - | AbbVie | |
| A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | NCT02951117 | Multiple Myelom... | Venetoclax ABBV-838 Dexamethasone | 18 Years - 99 Years | AbbVie | |
| A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) | NCT04509622 | Acute Myeloid L... | Venetoclax Cytarabine | 18 Years - | AbbVie | |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | NCT05861050 | Blastoid Varian... Mantle Cell Lym... Pleomorphic Var... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Glofitamab Lenalidomide Obinutuzumab Positron Emissi... Venetoclax | 18 Years - 80 Years | City of Hope Medical Center | |
| Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | NCT03609593 | Chronic Lymphoc... | Bendamustine Venetoclax Rituximab | 18 Years - 99 Years | Columbia University | |
| Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT04898894 | Acute Leukemia ... Acute Myeloid L... Refractory Acut... Refractory Acut... | Venetoclax Selinexor Cytarabine Fludarabine Filgrastim Methotrexate methotrexate/hy... | 2 Years - 30 Years | St. Jude Children's Research Hospital | |
| Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 | NCT04589728 | Acute Myeloid L... | Venetoclax plus... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | NCT05520567 | Acute Myeloid L... FLT3-mutated Ac... | Gilteritinib Venetoclax Azacitidine | 18 Years - | Astellas Pharma Inc | |
| A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04790903 | Lymphoma, Large... | Venetoclax Polatuzumab Ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - | Hoffmann-La Roche | |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | NCT03534180 | Anaplastic Larg... Recurrent Matur... Refractory Matu... | Laboratory Biom... Romidepsin Venetoclax | 18 Years - | City of Hope Medical Center | |
| Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas | NCT03036904 | Diffuse Large B... High Grade B-Ce... | Venetoclax Rituximab Etoposide Vincristine Sul... Cyclophosphamid... Prednisone Doxorubicin Hyd... | 18 Years - 80 Years | Weill Medical College of Cornell University | |
| Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas | NCT03036904 | Diffuse Large B... High Grade B-Ce... | Venetoclax Rituximab Etoposide Vincristine Sul... Cyclophosphamid... Prednisone Doxorubicin Hyd... | 18 Years - 80 Years | Weill Medical College of Cornell University | |
| A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | NCT04298918 | Breast Cancer | Placebo Venetoclax Trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | NCT05356169 | Acute Myeloid L... | with or without... | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | NCT05736965 | AML, Adult | Selinexor Azacitidine Venetoclax | 18 Years - | Shanghai Tong Ren Hospital | |
| Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | NCT03629171 | Recurrent Acute... Refractory Acut... | Liposome-encaps... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | NCT05155709 | Acute Myeloid L... | siremadlin venetoclax azacitidine | 18 Years - 99 Years | Novartis | |
| Expanded Access to Navitoclax | NCT03592576 | Myelofibrosis Acute Lymphocyt... Lymphoblastic L... | Navitoclax Venetoclax | 4 Years - | AbbVie | |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets | NCT05215639 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | NCT06085638 | Chronic Myelomo... | Azacitidine Tamibarotene Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | NCT02203773 | Acute Myelogeno... Myelogenous Leu... Treatment Naive... | Posaconazole ABT-199 Decitabine Azacitidine | 60 Years - | AbbVie | |
| Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | NCT05362942 | Relapsed Acute ... Refractory Acut... Minimal Residua... | Venetoclax, Dec... | 18 Years - | Beijing 302 Hospital | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | NCT04659044 | Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal... | Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax | 18 Years - | Academic and Community Cancer Research United | |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada | NCT05424562 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| Safe Accelerated Venetoclax Escalation in CLL | NCT04843904 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | NCT04739813 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | NCT05268003 | Acute Lymphobla... Leukemia | Ponatinib Venetoclax Mini-hyper CVD | 12 Years - | M.D. Anderson Cancer Center | |
| Safe Accelerated Venetoclax Escalation in CLL | NCT04843904 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | NCT04801797 | Acute Myeloid L... | Cytarabine Idarubicin Daunorubicin Liposomal dauno... Venetoclax Azacitidine | 18 Years - | Massachusetts General Hospital | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| A Study Of The Selective PKC-β Inhibitor MS- 553 | NCT03492125 | Chronic Lymphoc... Small Lymphocyt... Aggressive Lymp... | MS-553 MS-553 acalabrutinib venetoclax Rituximab obinutuzumab | 18 Years - | MingSight Pharmaceuticals, Inc | |
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting | NCT03342144 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| CIML NK Cells With Venetoclax for AML | NCT06152809 | Acute Myeloid L... Acute Myeloid L... Leukemia Leukemia, Myelo... | Cytokine-Induce... Interleukin-2 Venetoclax | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan | NCT06362044 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | NCT06042725 | Multiple Myelom... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Chest Radiograp... Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Low Dose Comput... Magnetic Resona... Positron Emissi... Venetoclax X-Ray Imaging Questionnaire A... | 18 Years - | Mayo Clinic | |
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | NCT06284486 | Acute Myeloid L... | Venetoclax Revumenib | 12 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 | NCT03255096 | Diffuse Large B... High-Grade B-ce... | RO6870810 Venetoclax Rituximab | 18 Years - | Hoffmann-La Roche | |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | NCT04487106 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Trametinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma | NCT03713580 | Non-hodgkin Lym... | Venetoclax | 18 Years - | Case Comprehensive Cancer Center | |
| Study to Evaluate CCS1477 in Haematological Malignancies | NCT04068597 | Haematological ... Acute Myeloid L... Non Hodgkin Lym... Multiple Myelom... Higher-risk Mye... Peripheral T Ce... | CCS1477 Pomalidomide Dexamethasone Azacitidine Venetoclax | 18 Years - | CellCentric Ltd. | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | NCT04657081 | Acute Myeloid L... | Decitabine and ... Venetoclax | 18 Years - | Astex Pharmaceuticals, Inc. | |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia | NCT05587049 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | NCT05005299 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Lymph... Myelodysplastic... Non-hodgkin Lym... Plasma Cell Mye... | Venetoclax Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Melbourne Health | |
| Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia | NCT04813263 | Acute Myeloid L... | - | AbbVie | ||
| A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy | NCT03785184 | Multiple Myelom... | venetoclax lenalidomide dexamethasone | 18 Years - | AbbVie | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening | NCT04267081 | Acute Myeloid L... | Venetoclax | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics | NCT06295029 | Acute Myeloid L... | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | ||
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT02992522 | B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell | Lenalidomide Obinutuzumab Venetoclax | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT02992522 | B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell | Lenalidomide Obinutuzumab Venetoclax | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT03399539 | Recurrent Plasm... t(11;14) | Dexamethasone Ixazomib Citrat... Laboratory Biom... Venetoclax | 18 Years - | Mayo Clinic | |
| A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | NCT05197192 | Chronic Lymphoc... | Obinutuzumab Venetoclax Acalabrutinib | 18 Years - 120 Years | German CLL Study Group | |
| Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer | NCT03900884 | Breast Neoplasm... | Venetoclax Palbociclib Letrozole | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT06191978 | Acute Myeloid L... | ASTX727 Venetoclax | 2 Years - 18 Years | M.D. Anderson Cancer Center | |
| A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT01671904 | Chronic Lymphoc... | Bendamustine Obinutuzumab Rituximab Venetoclax | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | NCT04029688 | Acute Myeloid L... Acute Lymphobla... Neuroblastoma Solid Tumors | Idasanutlin Venetoclax Cyclophosphamid... Topotecan Fludarabine Cytarabine Intrathecal Che... | 0 Years - 30 Years | Hoffmann-La Roche | |
| Venetoclax After TKI to Target Persisting Stem Cells in CML | NCT05701215 | Chronic Myeloid... | Venetoclax | 18 Years - | University of Jena | |
| This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax | NCT03343678 | Leukemia, Lymph... | Venetoclax BI 836826 | 18 Years - | Boehringer Ingelheim | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia | NCT04284787 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute... | Azacitidine Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Pembrolizumab Venetoclax | 60 Years - | National Cancer Institute (NCI) | |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies | NCT05292664 | Myelodysplastic... Myelodysplastic... Myelodysplastic... Treatment-Relat... Therapy-Related... Acute Lymphobla... Acute Lymphobla... Lymphoblastic L... Lymphoblastic L... Acute Leukemia ... Acute Leukemia ... | Venetoclax Azacitidine Cytarabine Methotrexate Hydrocortisone Leucovorin Dexamethasone Vincristine Doxorubicin Dexrazoxane Calaspargase Pe... Erwinia asparag... | 1 Year - 40 Years | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
